Healthcare M&A » By The Online Investor Staff, updated Wed., Jun. 29, 10:05 AM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #19 of 100 |
Slide #19. Bristol-Myers Squibb — iPierian, Inc.
Acquirer:
Bristol-Myers Squibb (NYSE:BMY)
Acquiree:
iPierian, Inc.
Details:
Bristol-Myers Squibb Company (NYSE:BMY) and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
Bristol-Myers Squibb SEC Filing Email Alerts Service
Open the BMY Page at The Online Investor »
|
|||||||||||||||||||||
Open the BMY Page at The Online Investor (in a new window) »
 Free BMY Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (2.85 out of 4) 9th percentile
(ranked lower than approx. 91% of all stocks covered)
Analysts' Target Price: BMY Stock Forecast Based on Zacks ABR data; powered by Xignite |
